Clinical Trials Browser

Phase 3 × INDUSTRY × Panitumumab × Clear all

NCT05198934 2026-04-27

CodeBreak300

Phase 3 Completed

160 enrolled 1 FDA

Gastrointestinal

Colorectal Neoplasms

NCT06252649 2026-04-24

CodeBreaK 301

Phase 3 Recruiting

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT02394795 2023-11-01

PARADIGM

Phase 3 Completed

823 enrolled 20 charts

Gastrointestinal

Colorectal Neoplasms

NCT00113763 2022-11-07

Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer

Phase 3 Completed

463 enrolled 17 charts

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00364013 2022-11-07

PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy

Phase 3 Completed

1,183 enrolled 18 charts

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT00339183 2022-09-23

Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone

Phase 3 Completed

1,186 enrolled 18 charts

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT01001377 2022-09-21

ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Phase 3 Completed

1,010 enrolled 22 charts

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT00115765 2018-10-17

PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study

Phase 3 Completed

1,053 enrolled 25 charts

Gastrointestinal

Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT01412957 2017-03-15

Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer

Phase 3 Completed

377 enrolled 20 charts

Gastrointestinal

Colorectal Neoplasms